United Therapeutics (NASDAQ:UTHR) Price Target Raised to $566.00

United Therapeutics (NASDAQ:UTHR) had its price objective increased by Morgan Stanley from $515.00 to $566.00 in a research note published on Wednesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on UTHR. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. The Goldman Sachs Group initiated coverage on United Therapeutics in a research report on Thursday, September 24th. They set a “sell” rating and a $321.00 price target for the company. Royal Bank Of Canada dropped their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research note on Thursday, October 1st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $627.31.

United Therapeutics Price Performance

NASDAQ UTHR opened at $549.16 on Wednesday. The company has a fifty day moving average price of $512.00 and a 200-day moving average price of $540.00. The firm has a market cap of $23.55 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 2.65 and a beta of 0.49. United Therapeutics has a 1 year low of $409.07 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the firm earned $6.41 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics will post 26.40 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $564.95, for a total value of $4,689,085.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,519,921.40. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $548.95, for a total value of $5,215,025.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $178,102,984.85. The trade was a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 364,728 shares of company stock valued at $187,920,726. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Toth Financial Advisory Corp increased its holdings in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics during the second quarter valued at about $30,000. Caitlin John LLC purchased a new stake in United Therapeutics during the second quarter valued at about $37,000. International Assets Investment Management LLC boosted its position in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new position in United Therapeutics during the second quarter worth about $81,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.